CAR-T Cell-Mediated B-Cell Depletion in Central Nervous System Autoimmunity.

Area of Science:

• Immunology
• Neuroscience
• Cell Therapy

Background:

• Anti-CD20 monoclonal antibody (mAb) therapy is effective for multiple sclerosis (MS).
• Chimeric antigen receptor (CAR)-T cells offer deeper tissue penetration than mAbs.
• Previous studies suggested anti-CD19 CAR-T cells may worsen experimental autoimmune encephalomyelitis (EAE).

Purpose of the Study:

• To investigate the efficacy of anti-CD19 CAR-T cells in a B-cell-dependent EAE model.
• To compare anti-CD19 CAR-T cell therapy with anti-CD20 mAb treatment for MS-like conditions.

Main Methods:

• Mice with B-cell-dependent EAE were treated with anti-CD19 CAR-T cells and cyclophosphamide (Cy).
• Evaluated B-cell depletion in lymphoid tissues and the CNS.
• Assessed clinical and histological EAE scores and immune modulation.

Main Results:

• Anti-CD19 CAR-T cells with Cy reduced clinical scores and lymphocyte infiltration in EAE mice.
• Complete B-cell depletion was observed in peripheral tissues and the CNS.
• Therapeutic effects were independent of antigen specificity or B-cell depletion.

Conclusions:

• Anti-CD19 CAR-T cells ameliorated EAE, contradicting previous findings.
• B-cell depletion within the CNS by CAR-T cells is achievable.
• The clinical benefit of anti-CD19 CAR-T cells in this model was not solely dependent on antigen targeting or B-cell depletion.